Risk of Hemolytic Anemia in IBD Patients with Glucose-6-Phosphate Dehydrogenase Deficiency Treated with Mesalamine: Results of a Retrospective-Prospective and Ex Vivo Study.
Giovanni Mario PesGiulia TomassiniChiara RocchiMilutin BulajicMonica CartaAlessandra ErrigoAlberto DimaggioFederica PadeddaGiovanni Mario PesPublished in: Journal of clinical medicine (2023)
This study provides, for the first time, evidence that mesalamine is safe in G6PD deficiency at a dosage of up to 4500 mg/day.